Blood glucose, without the needle.
Our foundational technology measures blood glucose without a fingerprick or a strip — the defensible IP the whole Diagnovate platform is built on. It's currently in ICMR-linked clinical validation in India.
Measure, model, report — no blood drawn.
A non-invasive read, a calibrated model trained on thousands of paired reference readings, and a result in seconds.
Non-invasive capture
The sensor captures a glucose-correlated signal from the body with no fingerprick, no strip and no consumable — the read is completely painless.
Calibrated model
A model calibrated against thousands of paired glucometer reference readings converts the raw signal into an estimated blood-glucose value.
Result & trend
The value flows into the Family Health AI record, so a single reading becomes a longitudinal glucose trend the agent can watch.
The moat under the platform.
Four compounding advantages that make a non-invasive glucose read genuinely hard to copy — and more valuable with every scan.
Painless = adherence
Diabetics avoid fingerpricks. Removing the needle changes how often people actually test — the whole point of a monitoring platform.
Clinical validation in progress
Under ICMR-linked trials with calibration work at IIT Patna and IHFC Delhi — regulatory evidence competitors would have to rebuild from scratch.
Data compounding
Every paired reading improves the calibration model. The dataset is the durable advantage, and it grows with every kiosk and device deployed.
Platform pull-through
Glucose is the anchor metric for India's metabolic-disease burden. Owning a non-invasive read pulls users into the kiosk, the meter and the AI.
Where the technology stands today.
The method, the validation pipeline and where it goes next — at a glance.
Investors, partners and clinicians — let's talk.
If the non-invasive glucometer is relevant to what you're building or backing, reach out and we'll share more under the right terms.